IOM prioritizes OTC contraceptive, supplement research
This article was originally published in The Tan Sheet
Executive Summary
An Institute of Medicine 1report to Congress on priority topics for comparative effectiveness research lists research on "innovative strategies for preventing unintended pregnancies" - including OTC access to oral contraceptives and other hormonal methods - as a top-tier priority. Lower-level items in the inventory of 100 priorities include comparing the effectiveness of dietary supplements in treating prevalent conditions, smoking-cessation strategies in minority and adolescent populations, and consumer self-care in avoiding early morbidity among people with mental illness. IOM submitted the report June 30 as required by the American Recovery and Reinvestment Act of 2009. The law charged IOM with recommending projects the Department of Health and Human Services should fund with the $1.1 billion allocated for CER (2"The Tan Sheet" March 16, 2009)
You may also be interested in...
Baucus Maintains Public/Private Comparative Effectiveness Vision
Senate Finance Committee Chairman Max Baucus continues planning to include comparative effectiveness in the health care reform debate, even with research funding included in the American Recovery and Reinvestment Act
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.